Ipsen's
elafibranor, marketed under the name Iqirvo, has secured accelerated approval from the FDA for the treatment of
primary biliary cholangitis (PBC) in adults. This marks a significant milestone as it is the first new medication for PBC in almost ten years. The approval follows impressive outcomes from the phase 3 ELATIVE trial, which demonstrated considerable biochemical response improvements over current treatments. In the trial, 70% of patients treated with elafibranor exhibited biochemical improvements, whereas no improvements were observed in the placebo group. These improvements were gauged by reduced levels of
alkaline phosphatase and total bilirubin. Additionally, Iqirvo showed benefits in enhancing the quality of life for patients suffering from
itch-related symptoms.
PBC is a rare autoimmune
liver disease that affects approximately 100,000 individuals in the United States. If left untreated, it can progress to
liver failure. Iqirvo offers a new treatment option for patients who do not respond adequately to
ursodeoxycholic acid (UDCA) or cannot tolerate it. Approved for use either in combination with UDCA or as a standalone therapy, it provides an alternative for managing this challenging condition.
Iqirvo is a pioneering medication belonging to a new class, designed as an oral, once-daily
peroxisome proliferator-activated receptor (PPAR) agonist. By activating PPAR receptors, Iqirvo aids in the regulation of gene expression related to lipid metabolism and
inflammation, presenting a novel mechanism of action distinct from existing treatments.
In addition to its FDA approval, Iqirvo is currently under review by the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency, with decisions anticipated later this year.
Meanwhile,
Gilead is also in pursuit of approval for another PBC treatment,
seladelpar. Acquired through its recent $4.3 billion purchase of
CymaBay Therapeutics, seladelpar is an oral
PPAR-delta agonist aimed at liver disease pathways. In its phase 3 trial, 70% of patients responded positively to seladelpar, with 37% achieving normal biomarker levels. The FDA has granted seladelpar priority review status, with an expected decision in August.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
